Soligenix (SNGX) Change in Account Payables (2010 - 2016)
Soligenix's (SNGX) quarterly Change in Account Payables came in at -$64796.0 in Q2 2016, down 170.05% YoY from $92505.0 in Q3 2015, and down 125.63% on a QoQ basis from $252835.0 in Q1 2016.
Soligenix (SNGX) Change in Account Payables (2010 - 2016) Analysis & Trends
Soligenix (SNGX) has 7 years of Change in Account Payables data on file, last reported at -$64796.0 in Q2 2016.
- Quarterly Change in Account Payables fell 170.05% year-over-year to -$64796.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $1.9 million (up 187.92% YoY) and the FY2015 annual result came in at $1.4 million, down 7.2% from the prior year.
- Change in Account Payables eased to -$64796.0 in Q2 2016, from $252835.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.7 million in Q3 2015 to a low of -$459603.0 in Q1 2015.
- A 5-year average of $181356.6 and a median of $32426.5 in 2014 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2012 — Change in Account Payables tumbled 9542.84% — and 2014, when it jumped 827.91%.
- Tracing SNGX's Change in Account Payables over 5 years: stood at $100780.0 in 2012, then soared by 203.34% to $305705.0 in 2013, then plunged by 118.25% to -$55781.0 in 2014, then soared by 158.29% to $32515.0 in 2015, then plunged by 299.28% to -$64796.0 in 2016.
- The last three Change in Account Payables figures came in at -$64796.0 (Q2 2016), $252835.0 (Q1 2016), and $32515.0 (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -64,796.00 |
| Jun 30, 2016 | -64,796.00 |
| Mar 31, 2016 | 252,835.00 |
| Mar 31, 2016 | 252,835.00 |
| Dec 31, 2015 | 32,515.00 |
| Dec 31, 2015 | 32,515.00 |
| Sep 30, 2015 | 1.71 Mn |
| Sep 30, 2015 | 1.71 Mn |
| Jun 30, 2015 | 92,505.00 |
| Jun 30, 2015 | 92,505.00 |
| Mar 31, 2015 | -459,603.00 |
| Mar 31, 2015 | -459,603.00 |
| Dec 31, 2014 | -55,781.00 |
| Dec 31, 2014 | -55,781.00 |
| Sep 30, 2014 | 1.09 Mn |
| Sep 30, 2014 | 1.09 Mn |
| Jun 30, 2014 | 412,971.00 |
| Jun 30, 2014 | 412,971.00 |
| Mar 31, 2014 | 32,338.00 |
| Mar 31, 2014 | 32,338.00 |